Grant Yonehiro Biography and Net Worth

COO of Bolt Biotherapeutics

Grant Yonehiro, Chief Operating Officer, joined Bolt Biotherapeutics in 2016. Mr. Yonehiro has been responsible for business and corporate development, strategy, commercialization, and general management within biotechnology companies for over 25 years with significant transactional and operational responsibilities. He served as president and chief executive officer of Perseid Therapeutics from inception through acquisition by Astellas Pharma and stayed on post-acquisition as president of an Astellas operating site. He served as chief business officer for Berkeley Lights and Maxygen Inc., and held various senior management positions at GenVec, Inc., including vice president of commercial operations, vice president of product management and vice president of drug development. Prior to GenVec, he served in business development at Cell Genesys, Inc. in investment banking at Piper Jaffray and in the Technology Transfer Office at Lawrence Berkeley National Laboratory.

Mr. Yonehiro graduated magna cum laude from the University of Minnesota with a Bachelor of Individualized Studies and received his MBA from the Haas School of Business at University of California, Berkeley.

What is Grant Yonehiro's net worth?: The estimated net worth of Grant Yonehiro is at least $86.83 thousand as of September 17th, 2026. Mr. Yonehiro owns 24,119 shares of Bolt Biotherapeutics stock worth more than $86,828 as of October 8th. This net worth evaluation does not reflect any other assets that Mr. Yonehiro may own. Learn More about Grant Yonehiro's net worth.
How do I contact Grant Yonehiro?: The corporate mailing address for Mr. Yonehiro and other Bolt Biotherapeutics executives is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. Bolt Biotherapeutics can also be reached via phone at 650-665-9295 and via email at [email protected]. Learn More on Grant Yonehiro's contact information.
Has Grant Yonehiro been buying or selling shares of Bolt Biotherapeutics?: Grant Yonehiro has not been actively trading shares of Bolt Biotherapeutics in the last ninety days. Most recently, Grant Yonehiro sold 6,850 shares of the business's stock in a transaction on Friday, September 18th. The shares were sold at an average price of $3.24, for a transaction totalling $22,194.00. Following the completion of the sale, the chief operating officer now directly owns 17,269 shares of the company's stock, valued at $55,951.56. Learn More on Grant Yonehiro's trading history.
Who are Bolt Biotherapeutics' active insiders?: Bolt Biotherapeutics' insider roster includes William Quinn (CFO), and Grant Yonehiro (COO). Learn More on Bolt Biotherapeutics' active insiders.
Are insiders buying or selling shares of Bolt Biotherapeutics?: In the last twelve months, Bolt Biotherapeutics insiders bought shares 4 times. They purchased a total of 1,396 shares worth more than $5,598.98. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 38,584 shares worth more than $128,361.21. The most recent insider tranaction occured on September, 18th when COO Grant Yonehiro sold 6,850 shares worth more than $22,194.00. Insiders at Bolt Biotherapeutics own 9.4% of the company. Learn More about insider trades at Bolt Biotherapeutics.
Information on this page was last updated on 9/18/2026.

Grant Yonehiro Insider Trading History at Bolt Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/18/2026	Sell	6,850	$3.24	$22,194.00	17,269
9/17/2026	Sell	4,909	$3.32	$16,297.88	24,119
9/16/2026	Sell	1,417	$3.77	$5,342.09	29,028

Grant Yonehiro Buying and Selling Activity at Bolt Biotherapeutics

Bolt Biotherapeutics Company Overview

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Today's Range

Now: $3.68

$3.38

$3.79

50 Day Range

MA: $3.71

$3.20

$4.07

2 Week Range

Now: $3.68

$3.10

$7.20

Volume

54,001 shs

Average Volume

38,593 shs

Market Capitalization

$7.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Grant Yonehiro Biography and Net Worth

What is Grant Yonehiro's net worth?

How do I contact Grant Yonehiro?

Has Grant Yonehiro been buying or selling shares of Bolt Biotherapeutics?

Who are Bolt Biotherapeutics' active insiders?

Are insiders buying or selling shares of Bolt Biotherapeutics?